Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents

E. GARCÍA-GARAYOA，

R. SCHIBLI，

P.A. SCHUBIGER

Nuclear Science and Techniques

Vol.18, No.2

pp.88-100

Published in print 20 Apr 2007

DOI：10.1016/S1001-8042(07)60026-8

CLC：Q516,R817

27900

Small peptide-based compounds have attracted an enormous interest as carrier molecules to selectively deliver radionuclides to target tissues, sparing critical normal organs. When looking for "matched pairs" of radionuclides, suitable for radiolabeling of peptides for diagnosis and therapy, technetium and rhenium represent an almost ideal constellation. The important role of technetium-99m and Re-186/188 is based on the decay characteristics, suitable for tumor diagnosis and therapy. Tc-99m and Re-188 are readily available by either a ⁹⁹Mo/^99mTc or the ¹⁸⁸W/¹⁸⁸Re radionuclide generator system. Furthermore, technetium and rhenium are chemically related and share structural as well as reactive similarities, which prompt an attractive "matched-pair" situation. This article shows an overview of ^99mTc- and ^186/188Re-radiolabeled peptides that have been tested for their potential use as imaging and therapeutic agents in oncological diseases.

Radiolabeled peptidesImagingTherapyOncologyTechnetium-99mRhenium-186/188

References

[1]

Liu S, Edwards D S. Chem Revs, 1999, 99: 2235-2268.

[2]

Shigeta N, Matsuoka H, Osa A, et al. Journal of Radioanalytical and Nuclear Chemistry-Articles, 1996, 205: 85-92.

[3]

Ehrhardt G J, Blumer M E, Su F M, et al. Applied Radiation and Isotopes, 1997, 48: 1-4.

[4]

Lapi S, Ressler J J, Cox M E, et al. Technetium and rhenium and other metals in chemistry and nuclear medicine 7. Padua: SGE Editoriali, 2006: 593-596.

[5]

Hohn A, Hirzel W, Schibli R. Technetium and rhenium and other metals in chemistry and nuclear medicine 7. Padua, 2006: 609-610.

[6]

Knapp F F, Mirzadeh S, Beets A L, et al. Technetium and rhenium in chemistry and nuclear medicine 4. Padua: SGE Editoriali, 1995: 319-324.

[7]

Liu G Z, Zhang S R, He J, et al. Bioconjugate Chem, 2002, 13: 893-897.

[8]

Liu G Z, Dou S P, He J, et al. Applied Radiation and Isotopes, 2006, 64: 971-978.

[9]

Thakur M L, Kolan H, Li J, et al. Nucl Med Biol, 1997, 24: 105-113.

[10]

Okarvi S M. Medicinal Research Reviews, 2004, 24: 357-397.

[11]

Liu S, Edwards D S, Looby R J, et al. Bioconjugate Chem, 1996, 7: 63-71.

[12]

Maina T, Nock B, Nikolopoulou A, et al. Eur J Nucl Med Mol Imaging, 2002, 29: 742-753.

[13]

Maina T, Stolz B, Albert R, et al. Eur J Nucl Med, 1994, 21: 437-444.

[14]

Harris T D, Sworin M, Williams N, et al. Bioconjugate Chem, 1999, 10: 808-814.

[15]

Edwards D S, Liu S, Barrett J A, et al. Bioconjugate Chem, 1997, 8: 146-154.

[16]

Kothari K K, Gali H, Prabhu K R, et al. Nucl Med Biol, 2002, 29: 83-89.

[17]

Gali H, Hoffman T J, Sieckman G L, et al. Bioconjugate Chem, 2001, 12: 354-363.

[18]

Karra S R, Schibli R, Gali H, et al. Bioconjugate Chem, 1999, 10: 254-260.

[19]

Alberto R, Schibli R, Egli A, et al. J Organomet. Chem, 1995, 493: 119-127.

[20]

Alberto R, Schibli R, Egli A, et al. J Am Chem Soc, 1998, 120: 7987-7988.

[21]

Alberto R, Schibli R, Schubiger A P, et al. J Am Chem Soc, 1999, 121: 6076-6077.

[22]

Egli A, Hegetschweiler K, Alberto R, et al. Organometallics, 1997, 16: 1833-1840.

[23]

Schibli R, Schwarzbach R, Alberto R, et al. Bioconjugate Chem, 2002, 13: 750-756.

[24]

Park S H, Seifert S, Pietzsch H J. Bioconjugate Chem, 2006, 17: 223-225.

[25]

Miao Y B, Owen N K, Whitener D, et al. Int J Cancer, 2002, 101: 480-487.

[26]

Boerman O C, Oyen W J G, Corstens F H M. Semin Nucl Med, 2000, 30: 195-208.

[27]

Merrifield B. Solid-Phase Peptide Synthesis. 1997: 3-13.

[28]

Wentworth P. Trends Biotechnol, 1999, 17: 448-452.

[29]

Lambert B, Cybulla M, Weiner S M, et al. Radiation Research, 2004, 161: 607-611.

[30]

Krenning E P, Kwekkeboom D J, Bakker W H, et al. Eur J Nucl Med, 1993, 20: 716-731.

[31]

Virgolini I, Raderer M, Kurtaran A, et al. New England Journal of Medicine, 1994, 331: 1116-1121.

[32]

Kwekkeboom D J, Krenning E P. Semin Nucl Med, 2002, 32: 84-91.

[33]

Menda Y, Kahn D. Semin Nucl Med, 2002, 32: 92-96.

[34]

Blum J, Handmaker H, Lister-James J, et al. Chest, 2000, 117: 1232-1238.

[35]

Decristoforo C, Mather S J, Cholewinski W, et al. Eur J Nucl Med, 2000, 27: 1318-1325.

[36]

Bangard M, Behe M, Guhlke S, et al. Eur J Nucl Med, 2000, 27: 628-637.

[37]

Marmion M E, Alberto R, Bugaj J, et al. J Labelled Compd Radiopharm, 1999, 42: S231-S233.

[38]

Schibli R, Schubiger A P. Eur J Nucl Med, 2002, 29: 1529-1541.

[39]

Wester H J. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18: 277-277.

[40]

Wester H J, Schottelius M, Schwaiger M. J Nucl Med, 2001, 42: 115P-115P.

[41]

Pearson D A, Lister-James J, McBride W J, et al. J Med Chem, 1996, 39: 1372-1382.

[42]

Zinn K R, Buchsbaum D J, Chaudhuri T R, et al. J Nucl Med, 2000, 41: 887-895.

[43]

Zamora P O, Bender H, Gulhke S, et al. Anticancer Res, 1997, 17: 1803-1808.

[44]

Bugaj J E, Bickel E M, Azure M T, et al. J Nucl Med, 2002, 43: 123P-123P.

[45]

Van de Wiele C, Dumont F, Van den Broecke R, et al. Eur J Nucl Med, 2000, 27: 1694-1699.

[46]

Nock B, Nikolopoulou A, Chiotellis E, et al. Eur J Nucl Med Mol Imaging, 2003, 30: 247-258.

[47]

Nock B A, Maina T, Behe M, et al. J Nucl Med, 2005, 46: 1727-1736.

[48]

Smith C J, Gali H, Sieckman G L, et al. Bioconjugate Chem, 2003, 14: 93-102.

[49]

Moustapha M E, Ehrhardt G J, Smith C J, et al. Nucl Med Biol, 2006, 33: 81-89.

[50]

Smith C J, Sieckman G L, Owen N K, et al. Anticancer Res, 2003, 23: 63-70.

[51]

Smith C J, Sieckman G L, Owen N K, et al. Cancer Res, 2003, 63: 4082-4088.

[52]

Garcia-Garayoa E, Ruegg D, Bläuenstein P, et al. Nucl Med Biol, 2006, in press.

[53]

Chen J Q, Giblin M F, Wang N N, et al. Nucl Med Biol, 1999, 26: 687-693.

[54]

Chen J Q, Cheng Z, Hoffman T J, et al. Cancer Res, 2000, 60: 5649-5658.

[55]

Miao Y B, Owen N K, Fisher D R, et al. J Nucl Med, 2005, 46: 121-129.

[56]

Dadachova E, Moadel T, Schweitzer A D, et al. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21: 117-129.

[57]

Reubi J C. Endocr Rev, 2003, 24: 389-427.

[58]

Buchegger F, Bonvin F, Kosinski M, et al. J Nucl Med, 2003, 44: 1649-1654.

[59]

Garcia-Garayoa E, Maes V, Blauenstein P, et al. Nucl Med Biol, 2006, 33: 495-503.

[60]

Blauenstein P, Garayoa E G, Ruegg D, et al. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19: 181-188.

[61]

Ruoslahti E, Pierschbacher M D. Science, 1987, 238: 491-497.

[62]

Hynes R O. Cell, 1992, 69: 11-25.

[63]

Sivolapenko G B, Skarlos D, Pectasides D, et al. Eur J Nucl Med Mol Imaging, 1998, 10: 1383-1389.

[64]

Costopoulos B, Benaki D, Pelecanou M, et al. Inorg Chem, 2004, 43: 5598-5602.

[65]

Gestin J F, Loussouarn A, Bardies M, et al. J Nucl Med, 2001, 42: 146-153.

[66]

Karacay H, McBride W J, Griffiths G L, et al. Bioconjugate Chem, 2000, 11: 842-854.

[67]

Reubi J C, Gugger M, Waser B. Eur J Nucl Med Mol Imaging, 2002, 29: 855-862.

[68]

Reubi J C, Waser B. Eur J Nucl Med Mol Imaging, 2003, 30: 781-793